Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 50,467 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CONTROL Clear all
Terminated Phase 2 Interventional Results available

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation

NCT00953706
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
34
States / cities
Birmingham, Alabama • Anchorage, Alaska • Oakland, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2015 · Synced Oct 19, 2026, 11:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fascial Closure Technique After Gynecologic Laparoscopic Surgery and Postoperative Pain

NCT04765306
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Traditional Direct Fascial Closure, Fascial Closure Device
Device
Lead sponsor
Jessica G Putman
Other
Eligibility
18 Years and older · Female only
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 19, 2026, 11:03 PM EDT
Completed Phase 2 Interventional Results available

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

NCT03546907
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
SAR440340, Placebo, Any Inhaled Corticosteroids as prescribed by treating physician as standard of care, Any Long Acting Beta Agonist as prescribed by treating physician as standard of care, Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care, Any short-acting β agonist as prescribed by treating physician as standard of care
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 75 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Los Angeles, California • Riverside, California • Rolling Hills Estates, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 19, 2026, 11:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants

NCT03320707
View directory record Official record
Conditions
Healthy
Interventions
Daratumumab, Placebo, rHuPH20
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 19, 2026, 11:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children

NCT02649192
View directory record Official record
Conditions
Healthy Participants
Interventions
Influenza virus vaccine, Vitamins A and D, Placebo
Biological · Dietary Supplement · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 8 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 19, 2026, 11:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Implementation of Practice Standards for ECG Monitoring

NCT01269736
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Education
Behavioral
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
92,057 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
14
States / cities
Long Beach, California • San Francisco, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 19, 2026, 11:03 PM EDT
Recruiting Not applicable Interventional

Talk With Me Baby: Leveraging Well-Child Care to Enhance the Early Home Language Environment

NCT07132411
View directory record Official record
Conditions
Child Language, Language Delay, Developmental Milestones
Interventions
Patients in Talk With Me Baby Clinics, Patients in Care-As-Usual Clinics
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
1 Day to 2 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Atlanta, Georgia • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 19, 2026, 11:03 PM EDT
Completed Phase 3 Interventional

A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)

NCT02462811
View directory record Official record
Conditions
Pain, Nausea, Vomiting
Interventions
CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg), Placebo, Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)
Drug
Lead sponsor
Joseph Hazelton
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 19, 2026, 11:03 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

4-day Plaque Accumulation Model Evaluating Compound Containing Gum

NCT06984744
View directory record Official record
Conditions
Dental Plaque Accumulation
Interventions
MIIP-E2 containing gum, placebo gum without MIIP-E2
Device
Lead sponsor
Lactea Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 19, 2026, 11:03 PM EDT
Recruiting Phase 2 Interventional

The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans

NCT06778434
View directory record Official record
Conditions
Actinic Keratosis, Imipramine, Photodynamic Therapy
Interventions
Imipramine, Control Vehicle
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 19, 2026, 11:03 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

First-in-Human Safety and Tolerability Study of OPF-110 in Healthy Adults

NCT07848334
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OPF-110, SMOFLIPID
Drug
Lead sponsor
Otsuka Pharmaceutical Factory, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 19, 2026, 11:03 PM EDT
Active, not recruiting Not applicable Interventional

Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

NCT06735534
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
FARAPULSE™ Pulsed Field Ablation System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
33
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 19, 2026, 11:03 PM EDT
Recruiting No phase listed Observational

Cognitive Impact of Neoadjuvant Chemotherapy for Gynecologic Cancers

NCT07125209
View directory record Official record
Conditions
Ovarian Cancer, Cognitive Change
Interventions
Patient Reported Outcomes Assessment, Cognitive and General Health Assessments
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 19, 2026, 11:03 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy

NCT03030599
View directory record Official record
Conditions
Narcolepsy With Cataplexy
Interventions
JZP-258, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
12
States / cities
Orange, California • Stanford, California • Boulder, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 19, 2026, 11:03 PM EDT
Completed No phase listed Observational

Comparing Wound Area Reduction of Non-healing DFUs Using MolecuLight i:X Versus Standard of Care

NCT04207099
View directory record Official record
Conditions
Non Healing Diabetic Foot Ulcer
Interventions
MolecuLight i:X Imaging Device
Device
Lead sponsor
MolecuLight Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Vista, California • Lake Success, New York • Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 19, 2026, 11:03 PM EDT
Completed Not applicable Interventional Results available

Selecting Effective Combinations of Treatment for Low Back Pain

NCT03520387
View directory record Official record
Conditions
Low Back Pain
Interventions
Lumbar medial branch nerve radiofrequency ablation (LRFA), Simulated LRFA with targeted steroid injections, AcTIVE-CBT, TBSCE
Procedure · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 19, 2026, 11:03 PM EDT
Withdrawn Not applicable Interventional

Medical-legal Partnership (MLP) to Support Bone Marrow Transplant

NCT02087787
View directory record Official record
Conditions
Blood or Marrow Transplant
Interventions
BMT Legal Clinic
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 19, 2026, 11:03 PM EDT
Recruiting Phase 1 Interventional

Dose-Escalation Study of Artesunate Patients With IPF

NCT05988463
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Artesuante, Placebo capsules
Drug · Other
Lead sponsor
Joseph C. Wu
Other
Eligibility
40 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 19, 2026, 11:03 PM EDT
Withdrawn Early Phase 1 Interventional

Relapse Prevention in Stimulant Use Disorder

NCT04553263
View directory record Official record
Conditions
Stimulant Use, Relapse, Cognitive Function, ADHD
Interventions
Contrave 8Mg-90Mg Extended-Release Tablet, Bupropion
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 19, 2026, 11:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PrEP2Prevent An Online PrEP Navigation and Activation Intervention

NCT05281393
View directory record Official record
Conditions
HIV Infections
Interventions
PrEPresent
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
16 Years to 26 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 19, 2026, 11:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Link for Schools: an Evaluation of a Tiered Staff Training Program and Student Intervention to Prevent Violence

NCT05196893
View directory record Official record
Conditions
Risk Reduction Behavior
Interventions
Link Intervention
Behavioral
Lead sponsor
Karen Heimer
Other
Eligibility
5 Years to 18 Years
Enrollment
863 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
3
States / cities
Cedar Rapids, Iowa • Iowa City, Iowa • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 19, 2026, 11:03 PM EDT
Completed No phase listed Observational

Multi-Center, Randomized Trial of the Pulsed Dye Laser for JORRP

NCT00550914
View directory record Official record
Conditions
Recurrent Respiratory Papillomatosis
Interventions
Not listed
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
1 Year to 12 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
San Diego, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2010 · Synced Oct 19, 2026, 11:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults

NCT00671814
View directory record Official record
Conditions
Healthy Subjects
Interventions
TR-701, linezolid, placebo
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 19, 2026, 11:03 PM EDT
Completed Not applicable Interventional

Graduated Recovery Intervention Program for Enhancing Treatment for First-Episode Psychosis

NCT00307216
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia
Interventions
Graduated Recovery Intervention Program (GRIP), Treatment as usual (TAU)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 19, 2026, 11:03 PM EDT